IOVANCE BIOTHERAPEUTICS, INC. reported Full year 2026 results: revenue $350 million to $370 million. Guidance initiated.
“Total product revenue guidance for 2Q26 is $86 million to $88 million and for FY26 is $350 million to $370 million”
IOVANCE BIOTHERAPEUTICS, INC. — fact timeline
Source-grounded facts extracted from IOVANCE BIOTHERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IOVANCE BIOTHERAPEUTICS, INC. reported Second quarter 2026 results: revenue $86 million to $88 million. Guidance initiated.
“Total product revenue guidance for 2Q26 is $86 million to $88 million”
IOVANCE BIOTHERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue ~$71 million.
“and long-term value for patients and shareholders.” First Quarter 2026 Financial Highlights Continued Strength in Execution and Cost Discipline · Total product revenue of ~$71 million increased by ~45% over 1Q25, reflecting significant performance improvements over the prior annual maintenance period. o U.S. Amtagvi revenue was ~$60 million. o Global”
Jean-Marc Bellemin resigned as Chief Financial Officer at IOVANCE BIOTHERAPEUTICS, INC..
“On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer and principal financial and accounting officer of Iovance Biotherapeutics, Inc. (the “Company”), provided the Company with written notice under his Executive Employment Agreement, dated November 23, 2020, that he would resign from the Company, effective July 10, 2025, to pursue other opportunities.”
IOVANCE BIOTHERAPEUTICS, INC. reported financial results for first quarter 2024.
“On May 9, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024”
IOVANCE BIOTHERAPEUTICS, INC.: Amended and restated bylaws to modify the definition of 'Acting in Concert' (effective 2024-03-28).
“On March 28, 2024, the Board unanimously adopted the Company’s Fourth Amended and Restated Bylaws”
Frederick G. Vogt was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..
“Frederick G. Vogt, Ph.D., J.D., the Company’s Interim Chief Executive Officer and President, and General Counsel, be nominated to stand for election to the Board at the Annual Meeting”
Merrill A. McPeak retired as Director at IOVANCE BIOTHERAPEUTICS, INC..
“General (Ret.) Merrill A. McPeak, a member of the Board of Directors (the “ Board ”) of Iovance Biotherapeutics, Inc. (the “ Company ”), provided notice to the Board that he will retire and not be standing for re-election to the Board at the Company’s annual meeting”
IOVANCE BIOTHERAPEUTICS, INC. reported year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $444.0 million, EPS $1.89 per share.
“Net loss for the year ended December 31, 2023 was $444.0 million, or $1.89 per share, compared to a net loss of $395.9 million, or $2.49 per share, for the year ended Dec”
IOVANCE BIOTHERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, EPS $0.45 per share.
“Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, or $0.45 per share, compared to a net loss of $105.3 million, or $0.64 per share, for the fourth quarter ended December 31, 2022.”
IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC valued at approximately $197.1 million (effective 2024-02-20).
“On February 20, 2024, Iovance Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,014,000 shares of common stock (the “Shares”) (the “Offering”).”
IOVANCE BIOTHERAPEUTICS, INC. reported financial results for third quarter and year-to-date 2023.
“Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates”
IOVANCE BIOTHERAPEUTICS, INC. reported financial results for second quarter and first half 2023.
“On August 8, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and an update on recent developments.”
IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC and Jefferies LLC valued at up to 23,000,000 shares of common stock at $7.50 per share (effective 2023-07-10).
“On July 10, 2023, Iovance Biotherapeutics, Inc. (the “Company”) entered in an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Jefferies LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,000,000 shares of common stock (the “Shares”), which includes 3,000,000 shares (the “Optional Shares”) that may be sold pursuant to a 30-day option to purchase additional shares granted to the Underwriters (the “Offering”).”
IOVANCE BIOTHERAPEUTICS, INC. terminated Prior Sales Agreement with Jefferies LLC (effective 2023-06-16).
“On June 16, 2023, the Company terminated its Open Market Sale Agreement, dated November 18, 2022, with Jefferies (the “ Prior Sales Agreement ”) related to the offer and sale of shares of the Company's common stock in at-the-market offerings.”
IOVANCE BIOTHERAPEUTICS, INC. entered into Sales Agreement with Jefferies LLC valued at up to $450.0 million (effective 2023-06-16).
“On June 16, 2023, Iovance Biotherapeutics, Inc. (the “ Company ”) entered into a new Open Market Sale Agreement (the “ Sales Agreement ”) with Jefferies LLC (“ Jefferies ”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $450.0 million of shares of the Company's common stock, par value $0.000041666 per share (the “ Common Shares ”).”
IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 500,000,000 shares at the 2023-06-06 meeting.
“This proposal was approved with 183,669,098 "FOR" votes, 6,762,171 "AGAINST" votes and 388,069 "ABSTAIN" votes. There were 0 broker non-votes in connection with this proposal.”
IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve an amendment to the 2020 Iovance Employee Stock Purchase Plan to increase the number of shares available for grant from 500,000 shares to 1,400,000 shares at the 2023-06-06 meeting.
“This proposal was approved with 166,626,237 "FOR" votes, 3,580,244 "AGAINST" votes and 327,914 "ABSTAIN" votes. There were 20,284,943 broker non-votes in connection with this proposal.”
IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve an amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant from 20,700,000 shares to 29,700,000 shares at the 2023-06-06 meeting.
“This proposal was approved with 163,183,808 "FOR" votes, 7,000,254 "AGAINST" votes and 350,333 "ABSTAIN" votes. There were 20,284,943 broker non-votes in connection with this proposal.”
IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
“This proposal was approved with 189,050,447 "FOR" votes, 1,427,679 "AGAINST" votes and 341,212 "ABSTAIN" votes. There were 0 broker non-votes in connection with this proposal.”
IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2023-06-06 meeting.
“This proposal was approved with 152,122,330 "FOR" votes, 18,005,962 "AGAINST" votes and 406,103 "ABSTAIN" votes. There were 20,284,943 broker non-votes in connection with this proposal.”
IOVANCE BIOTHERAPEUTICS, INC. shareholders approved Election of Iain Dukes, D. Phil., Athena Countouriotis, M.D., Ryan Maynard, Merrill A. McPeak, Wayne P. Rothbaum, Michael Weiser, M.D., Ph.D. and Wendy Yarno to the Board of Directors at the 2023-06-06 meeting.
“The voting results for the election of the director nominees were as follows: For Withheld Broker Non-Vote Dr. Dukes 148,807,931 21,726,464 20,284,943 Dr. Countouriotis 151,909,502 18,624,893 20,284,943 Mr. Maynard 154,930,213 15,604,182 20,284,943 General McPeak 91,979,426 78,554,969 20,284,943 Mr. Rothbaum 154,805,281 15,729,114 20,284,943 Dr. Weiser 148,314,345 22,220,050 20,284,943 Ms. Yarno 148,822,514 21,711,881 20,284,943”
IOVANCE BIOTHERAPEUTICS, INC. reported financial results for the quarter ended March 31, 2023.
“On May 9, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and an update on recent developments.”
Wendy L. Dixon departed as director at IOVANCE BIOTHERAPEUTICS, INC..
“Wendy L. Dixon, a member of the Board, will not be standing for re-election to the Board at the Company’s annual meeting of stockholders currently anticipated to be held in June 2023.”
Wendy L. Yarno was appointed as director at IOVANCE BIOTHERAPEUTICS, INC..
“appointed Wendy L. Yarno as a director and new member of the Board, effective April 18, 2023.”
IOVANCE BIOTHERAPEUTICS, INC. terminated Prior Sales Agreement with Jefferies (effective 2022-11-18).
“On November 18, 2022, the Company terminated its Open Market Sale Agreement, dated February 8, 2021, with Jefferies (the “Prior Sales Agreement”) related to the offer and sale of shares of the Company's common stock in at-the-market offerings.”
IOVANCE BIOTHERAPEUTICS, INC. entered into Sales Agreement with Jefferies LLC valued at $500.0 million (effective 2022-11-18).
“On November 18, 2022, the Company entered into a new Open Market Sale Agreement (the “ Sales Agreement ”) with Jefferies LLC (“Jefferies”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $500.0 million of shares of the Company's common stock, par value $0.000041666 per share (the “Common Shares”).”
IOVANCE BIOTHERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: net income $99.6 million, or $0.63 per share, EPS $0.63 per share.
“Net loss for the third quarter ended September 30, 2022, was $99.6 million, or $0.63 per share, compared to a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021.”
Wendy Dixon was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..
“appointed Wendy Dixon, Ph.D., as a director and new member of the Board, effective June 10, 2022, to fill such newly created vacancy.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.